ClinicalTrials.gg
CompletedNCT03029624Updated Dec 22, 2020Results posted

eCoin Tibial Nerve Stimulation for OAB

An interventional study of eCoin in Urgency Urinary Incontinence, sponsored by Valencia Technologies Corporation. Completed at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-22.

Sponsored by Valencia Technologies Corporation · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 293 studies in Urinary Incontinence with a site in United States — 33 open to participants now, 47 under way, 3 of them phase 3. Urinary Incontinence · United States.

Enrollment
150th of 249
46 · median 75
Started
2017
with 18 others
No phase
144 of 293
21 open now
Registered
146th of 293
by date

Among the 293 studies in Urinary Incontinence with a site in United States, this one is the 150th largest by enrollment of the 249 interventional ones that give a count, is one of 19 that started in 2017, is one of 144 with no phase, and was the 146th registered.

Urinary Incontinence

988 studies on the registry are indexed under Urinary Incontinence; 184 are open to participants now.

Browse Urinary Incontinence studies →

Open to participants now

33 of the 293 studies in Urinary Incontinence with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 113 Urinary Incontinence studies recruiting now, 63 (56%) set no upper age limit and 35 (31%) stop at 75 or younger; 15 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies in Urinary Incontinence with a site in United States, or all of them as a file.
02

Study summary

The study is a single arm, prospective study of the safety and effectiveness of the Valencia Technologies eCoin System to stimulate the tibial nerve for the treatment of patients with refractory urgency urinary incontinence.

Read the detailed description

This trial is a single arm, prospective study of the safety and effectiveness of eCoin tibial nerve stimulation in 25 subjects with refractory overactive bladder as defined by the American Urological Association.. The eCoin neuromodulation device will be implanted subcutaneously in the right or left leg of patients with urgency urinary incontinence. After a 4 week implant healing period, subjects will have their devices activated (turned ON). After 3 months of device therapy (occurring 4 months post-implant), the primary endpoint will be assessed. It is anticipated that subjects will reach the full therapeutic effect at approximately 3 months of therapy. Subjects will be followed for an additional 9 months to assess the safety of maintenance stimulation therapy with fewer sessions occurring during this time interval.

03

Conditions studied

  • Urgency Urinary Incontinence

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women and men 18 years and older.
  2. Diagnosis of overactive bladder with urgency urinary incontinence or mixed urge and stress incontinence with a predominant urgency component, for at least 6 months (self-reported).
  3. Individual has at least four urgency incontinence episodes on a three-day voiding diary with at least one episode per 24 hour time period
  4. Individual with urinary frequency, defined as an average of greater than or equal to 8 times/24 hours (ie. a total of greater than or equal to 24 micturitions on a 3 day diary)
  5. Individual is unresponsive to, inadequately responsive to, or intolerant of behavioral, rehabilitation, and pharmacologic therapy.
  6. Individual is able to give his or her written, .
  7. Individual is mentally competent and able to understand all study requirements.
  8. Individual is willing and able to complete a 3-day voiding diary and quality of life questionnaire.
  9. Individual is without pharmacological treatment of overactive bladder (antimuscarinics and beta-3 agonists) for 2 weeks prior to screening.
  10. The individual demonstrates a positive nerve integrity test.

Exclusion criteria

Exclusion Criteria:

  1. Individual has predominantly stress urinary incontinence
  2. Individual has bladder outlet obstruction.
  3. Individual has clinically significant pelvic organ prolapse.
  4. Individual has abnormal post void residual (i.e., greater than 150 cc).
  5. Individual has clinically significant urethral stricture disease or bladder neck contracture
  6. Individual has an active urinary tract infection at time of enrollment.
  7. Individual has recurrent urinary tract infections defined as 4 or more UTI's per year.
  8. Individual has morbid obesity.
  9. Individual has had positive urine cytology or diagnosis of bladder or prostate cancer.
  10. Individual has neurogenic bladder dysfunction.
  11. Individual is taking an alpha-blocker for benign prostatic hyperplasia.
  12. Individual is pregnant or intends to become pregnant during the study.
  13. Patient is breast feeding or is less than 9-month post-partum.
  14. Individual has the presence of urinary fistula, bladder stone, or interstitial cystitis.
  15. Individual has uncontrolled diabetes mellitus.
  16. Individual has a cardiac pacemaker or implanted defibrillator.
  17. Individual has been previously treated with sacral nerve stimulation.
  18. Individual has been treated with onabotulinumtoxinA in the previous 9 months prior to enrollment.
  19. Individual has been treated with percutaneous tibial nerve stimulation within the previous 12 weeks prior to enrollment.
  20. Individual requires regular Magnetic Resonance Imaging for other health care conditions. (ASK)
  21. Individual has a clotting or bleeding disorder; antiplatelet and anticoagulant therapy may be continued or held at the discretion of the investigator
  22. Individual has a clinically significant peripheral neuropathy.
  23. Individual is neutropenic or .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Treatment Arm

    Treatment Arm receives implanted eCoin device and therapy is turned ON.

    Device: eCoin

Interventions

  • DeviceeCoin

    Patients are implanted with active implantable device called eCoin. eCoin is turned ON in order to deliver neuromodulation therapy.

06

What researchers measure

Primary outcomes

  1. Incontinent Episodes

    The change in number of incontinence episodes from baseline to three months post-activation.

    Time frame: Baseline to three months post-activation.

Secondary outcomes

  1. System and Procedure Related AEs

    Number of System and Procedure Related Adverse Events from implantation to one month post-implantation.

    Time frame: Implantation to one month post-implantation.

  2. MAEs

    Number of all Major Adverse Events from baseline to 3 months post-activation.

    Time frame: Baseline to 3 months post-activation.

  3. Percentage of Responders

    Percentage of Responders, defined as participants who experienced a 50% or greater reduction in UUI after 3 months of treatment

    Time frame: 3 months after activation

07

Results

Posted Nov 27, 2020
Limitations and caveats
This was a small study with a nonrandomized design and no control group. Studies in larger populations may clarify the factors associated with responders. The initial study period was short at only 3 months, and should be investigated further for durability.

Participant flow

Participants were recruited and enrolled from April 2017 to September 2017 (i.e. 5 months). The study took place at 7 urology/urogynecology clinics across the United States and New Zealand.

Participant flow — Overall Study
MilestoneeCoin
Started46
Primary endpoint (3 months)44
Completed41
Not completed5
Withdrew: Adverse event1
Withdrew: Withdrawal by subject1
Withdrew: Lack of efficacy1
Withdrew: Mri need2

Outcome measures

PrimaryIncontinent Episodes

The change in number of incontinence episodes from baseline to three months post-activation.

Time frame:
Baseline to three months post-activation.
Reported as:
Median · episodes/day
Incontinent Episodes
episodes/dayeCoin
Incontinent Episodes-3.0 ± 2.9
SecondarySystem and Procedure Related AEs

Number of System and Procedure Related Adverse Events from implantation to one month post-implantation.

Time frame:
Implantation to one month post-implantation.
Reported as:
Number · Adverse Events
System and Procedure Related AEs
Adverse EventseCoin
System and Procedure Related AEs20
SecondaryMAEs

Number of all Major Adverse Events from baseline to 3 months post-activation.

Time frame:
Baseline to 3 months post-activation.
Reported as:
Number · Adverse Events
MAEs
Adverse EventsTreatment Arm
MAEs3
SecondaryPercentage of Responders

Percentage of Responders, defined as participants who experienced a 50% or greater reduction in UUI after 3 months of treatment

Time frame:
3 months after activation
Reported as:
Count of participants · Participants
Percentage of Responders
ParticipantseCoin
Percentage of Responders32

Adverse events

Collected over Adverse event data was collected from enrollment through 6 months after implantation.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
eCoin0/46 (0%)3/46 (6.5%)16/46 (34.8%)
Most frequent serious events
Most frequent serious events
EventeCoin
Cellulitis Secondary to Ankle WrapInfections and infestations1/46
Hip Bursitis & EdemaMusculoskeletal and connective tissue disorders1/46
PneumoniaInfections and infestations1/46
Most frequent other events
Most frequent other events
EventeCoin
Moderate implant site discomfort, swelling, pain, bruisingGeneral disorders5/46
Blister secondary to ankle wrapSkin and subcutaneous tissue disorders4/46
Mild swelling, bruising, discomfortGeneral disorders3/46
Possible incision site infectionInfections and infestations2/46
Stimulation painProduct Issues1/46
Device migration about 1 cm posteriorProduct Issues1/46

Baseline characteristics

Baseline analyses includes the baseline information for enrolled and implanted participants. Data on 3 participants were imputed per protocol.

Age, Continuous
Age, Continuous(years)eCoin
Mean63.39 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)eCoin
Female45
Male1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)eCoin
Hispanic or Latino0
Not Hispanic or Latino34
Unknown or Not Reported12
Race (NIH/OMB)
Race (NIH/OMB)(Participants)eCoin
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White45
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)eCoin
New Zealand20
United States26
Urinary incontinence
Urinary incontinence(episodes/day)eCoin
Mean5.9 ± 3.1
Urgency urinary incontinence
Urgency urinary incontinence(episodes/day)eCoin
Mean5.2 ± 2.9
No. OAB medication at screening
No. OAB medication at screening(Participants)eCoin
Count of participants9

2 further baseline measures are reported on the registry.

08

Study locations

7 sites
  • The Clark Center for Urogynecology
    Newport Beach, California 92663, United States
  • UnityPoint Clinic
    Waterloo, Iowa 50703, United States
  • Alliance Urology Specialists
    Greensboro, North Carolina 27403, United States
  • The Institute for Female Pelvic Medicine & Reconstructive Surgery (FPM Institute)
    Allentown, Pennsylvania 18103, United States
  • Urology Associates
    Christchurch, 8013, New Zealand
  • Roundhay Medical Centre
    Nelson, New Zealand
  • Tauranga Urology Research Ltd
    Tauranga, New Zealand
09

References and documents

Publications

  • Kaaki B, English S, Gilling P, Meffan P, Lucente V, MacDiarmid S, Clark M, Sen SK. Six-Month Outcomes of Reimplantation of a Coin-Sized Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome With Urgency Urinary Incontinence. Female Pelvic Med Reconstr Surg. 2022 May 1;28(5):287-292. doi: 10.1097/SPV.0000000000001105. Epub 2022 Sep 22. PubMed 35536667 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Dec 2017, 8 months.

Results were first posted in Nov 2020, 2 years 10 months after primary completion.

Of 63 industry-sponsored interventional studies with no phase under Urinary Incontinence, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 8 months is below that.

Counting every sponsor, half of 366 studies reached it within 15 months; a quarter within 7 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2017
First posted
Jan 24, 2017
StartActual
Apr 3, 2017
Primary completionActual
Dec 30, 2017
CompletionActual
Oct 1, 2018
Results first posted
Nov 27, 2020
Last update
Dec 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03029624
Lead sponsor
Valencia Technologies Corporation
Responsible party
Sponsor
First posted
Jan 24, 2017
Start date
Apr 3, 2017
Primary completion
Dec 30, 2017
Completion
Oct 1, 2018
Results posted
Nov 27, 2020
Last update
Dec 22, 2020

Study contacts

Sharon English, MD
principal investigator · Urology Associates
Scott MacDiarmid, MD
principal investigator · Alliance Urology Specialists

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion